+44 1625708989Formulation development and optimization of chirally pure S (+) Etodolac extended release tablets for the management of arthritis
Author(s): Srikant Pimple*, Pravin Maurya, Akash Joshi, Krupal Salunke, Ruby Singh, Mukund Gurjar and Mahesh ShahEtodolac is a non-steroidal anti-inflammatory drug effectively used in treatment of rheumatoid arthritis, osteoarthritis and in the relief of moderately severe post-surgical pain. S (+) Etodolac shows almost all the pharmacological activity, and more potent than its racemate, while R-Etodolac is almost inactive. The main objective of the present study was to formulate chirally pure S(+) Etodolac extended release tablets.S(+) Etodolac 300 mg is equivalent to Etodolac 600 mg. Based on the pre-formulation studies; excipients are selected for formulation development. The major criterion considered during the development of formulation was to match the dissolution profile of the drug product with the reference product.The extended release tablets were prepared by wet granulation technique using excipients likeCarbopol 974 P, HypromelloseK4M, PEG 6000, Povidone, and Colloidal Silicon Dioxide. Tablets were subjected to film coating to enhance aesthetic appeal. Formulation was designed to release the drug in extended release manner over a period of 16 hours using polymers like Carbopol 974 P and Hypromellose K4M. Several trials were taken to optimize the physical parameters of the tablets and the release kinetics of the drug product. The prepared tablets were evaluated for pre and post compression parameters. To analyze the in vitro release data various kinetic models were used to describe the release kinetics. In vitro drug release data were plotted in various models to find out the best fit model with higher correlation coefficient. Stability study was also performed and desirable results were obtained.
PDF